argenex (NASDAQ:ARGX) Upgraded by Wall Street Zen to Buy Rating

argenex (NASDAQ:ARGX) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Other analysts have also issued reports about the stock. Royal Bank Of Canada cut their target price on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday. Citizens Jmp upped their price target on argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a report on Friday. HC Wainwright raised their price objective on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a research note on Friday. Evercore lifted their target price on argenex from $775.00 to $910.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Finally, Truist Financial upped their target price on argenex from $950.00 to $1,030.00 and gave the company a “buy” rating in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $999.22.

argenex Stock Down 0.6%

Shares of ARGX stock opened at $766.92 on Friday. The stock has a 50-day simple moving average of $826.36 and a 200 day simple moving average of $810.76. The stock has a market capitalization of $47.46 billion, a P/E ratio of 39.29, a P/E/G ratio of 0.67 and a beta of 0.37. argenex has a fifty-two week low of $510.05 and a fifty-two week high of $934.62.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, February 26th. The company reported $8.02 EPS for the quarter, topping the consensus estimate of $6.05 by $1.97. argenex had a net margin of 30.42% and a return on equity of 63.59%. The firm had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.30 billion. On average, sell-side analysts anticipate that argenex will post 3.13 earnings per share for the current year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of argenex by 91.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,828 shares of the company’s stock worth $6,511,000 after purchasing an additional 4,217 shares in the last quarter. Allianz Asset Management GmbH grew its stake in argenex by 21.3% during the third quarter. Allianz Asset Management GmbH now owns 3,671 shares of the company’s stock worth $2,708,000 after buying an additional 645 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of argenex by 14.2% during the third quarter. Allspring Global Investments Holdings LLC now owns 211,330 shares of the company’s stock worth $162,160,000 after buying an additional 26,343 shares in the last quarter. Alta Wealth Advisors LLC bought a new position in shares of argenex in the third quarter valued at approximately $623,000. Finally, Fiera Capital Corp raised its stake in shares of argenex by 12.1% in the third quarter. Fiera Capital Corp now owns 177,654 shares of the company’s stock valued at $131,030,000 after acquiring an additional 19,180 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase‑3 topline results for VYVGART in ocular myasthenia gravis (ADAPT OCULUS); study met its primary endpoint and argenx plans a supplemental BLA submission to expand the label into oMG, which materially expands commercial opportunity. argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial
• Positive Sentiment: Strong quarterly and full‑year commercial performance: $1.3B in Q4 product net sales and $4.2B for FY2025 (≈90% YoY growth), reinforcing revenue momentum and the company’s commercialization traction. argenx Reports Full Year 2025 Financial Results
• Positive Sentiment: Q4 beat on the numbers: $8.02 EPS vs. $6.05 consensus and $1.32B revenue vs. $1.30B consensus, with healthy margins and ROE — data that supports higher earnings expectations. MarketBeat Q4 Earnings Summary
• Positive Sentiment: Certain sell‑side firms raised targets after the results (Citizens JMP and HC Wainwright among them), signaling continued analyst conviction in upside from commercialization and label expansion. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Other major firms trimmed price targets (Wells Fargo, Guggenheim, RBC) but generally maintained positive ratings (overweight/outperform/buy). These adjustments temper upside expectations but keep buy convictions intact. These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
• Neutral Sentiment: Reports flag a “large increase” in short interest for February, but the published short‑interest numbers appear inconsistent/erroneous (zeros/NaN). As reported data is unreliable, the market impact is unclear.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.